date,title,source
Oct-17-18,Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress,PR Newswire
Oct-18-18,EBS or ALKS: Which Is the Better Value Stock Right Now?,Zacks
Oct-19-18,Alkermes Boasts Strong Portfolio and Impressive Pipeline,Zacks
Oct-22-18,Alkermes Q3 Earnings Preview,Benzinga
Oct-22-18,"BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?",Zacks
Oct-23-18,Edited Transcript of ALKS earnings conference call or presentation 23-Oct-18 12:30pm GMT,Thomson Reuters StreetEvents
Oct-23-18,Alkermes PLC (ALKS) Q3 2018 Earnings Conference Call Transcript,Motley Fool
Oct-23-18,"Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook",Zacks
Oct-23-18,Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates,Zacks
Oct-23-18,Alkermes: 3Q Earnings Snapshot,Associated Press
Oct-23-18,Alkermes Plc Reports Third Quarter 2018 Financial Results,PR Newswire
Oct-24-18,Alkermes Makes Financial Progress as Its Pipeline Moves Forward,Motley Fool
Oct-24-18,Today's Research Reports on Trending Tickers: Alkermes and Amarin,ACCESSWIRE
Oct-29-18,FDA set to review new drugs aimed at fighting depression,CNBC Videos
Oct-29-18,Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry,PR Newswire
Oct-29-18,"Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?",Benzinga
Oct-30-18,Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drug,MarketWatch
Oct-31-18,"New Research: Key Drivers of Growth for Alkermes plc, PulteGroup, Las Vegas Sands, Barrick Gold, Avangrid, and Fomento Economico Mexicano S.A.B. de C.V  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Nov-01-18,Alkermes stock falls after FDA committee votes against depression drug,MarketWatch
Nov-01-18,Alkermes' depression treatment fails to get FDA panel backing,Reuters
Nov-01-18,Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder,PR Newswire
Nov-01-18,Alkermes depression drug in peril after FDA advisory vote,American City Business Journals
Nov-01-18,FDA panel votes against Alkermes' depression treatment,Reuters
Nov-01-18,"Alkermes depression drug facing FDA panel, here's what to...",CNBC Videos
Nov-01-18,Alkermes stock halted as FDA committee considers depression drug,MarketWatch
Nov-01-18,Trading in Alkermes Ordinary Shares Halted Today,PR Newswire
Nov-06-18,Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences,PR Newswire
Nov-06-18,Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting,PR Newswire
Nov-08-18,"Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A",Motley Fool
